Clinical Trial

A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.
Protocol Amendment History 1 change
notable Trial sites expanded: 0 -> 3 locations 2026-06-19
Trial Details
NCT Number NCT07607925
Lead Sponsor GlaxoSmithKline
Conditions Lymphoma, Non-Hodgkin
Enrollment 49 participants
Start Date 2026-06-12
Primary Completion 2029-09-24 (estimated)
Study Completion 2029-09-24 (estimated)
Updated on ClinicalTrials.gov 2026-06-18